4.2.2 Antipsychotic depot injections

Homepage

Search the NeLM

Medicines A-Z

Find key information about medicines by name (prototype)

Browse by Categories:

Browse by NeLM area:

BNF Category

62 library items in 4.2.2 Antipsychotic depot injections

Filter results by:

Date Published

NeLM Area

News
Other Library Updates
Health In Focus
Evidence
Medicines A-Z
Communities
Formularies

Results filtered by:

Category

4: Central nervous system (remove) , 4.2 Drugs used in psychoses and related disorders (remove) , 4.2.2 Antipsychotic depot injections (remove)

Sort by: Display summary:

Results 1 - 10 of 62

Result page:
Previous
|
1
2
3
4
5
6
7
|
Next

1.

Monitoring and documentation of side effects from depot antipsychotic medication: an interdisciplinary audit of practice in a regional mental health service

Source: Journal of Psychiatric and Mental Health Nursing,
Date published: 02/05/2012

Category:

4.2.2 Antipsychotic depot injections | Adverse Drug Reactions

NeLM Area:

Evidence > Medicines Management > References

Abstract
2.

Which drugs can cause Neuroleptic Malignant Syndrome?

Source: Regional Drug and Therapeutics Centre,
Date published: 18/04/2012
Review date: 31/01/2014

Category:

1.2 Antispasmodics and other drugs altering gut motility | 4.2.1 Antipsychotic drugs | 4.2.2 Antipsychotic depot injections | 4.9.1 Dopaminergic drugs used in Parkinson's disease

NeLM Area:

Evidence > Medicines Q & A

Which drugs can cause neuroleptic malignant syndrome?
3.

NETAG issues recommendation on paliperidone depot injection (Xeplion®) following an appeal

Source: NETAG ,
Date published: 26/03/2012

Category:

4.2.2 Antipsychotic depot injections | Drug reviews | Schizophrenia and disorders with psychotic features

NeLM Area:

Evidence > Drug Specific Reviews

Link
4.

AWMSG issues Final Appraisal Recommendation on paliperidone palmitate (Xeplion®) prolonged release suspension for injection

Source: All Wales Medicines Strategy Group (AWMSG),
Date published: 19/01/2012

Category:

4.2.2 Antipsychotic depot injections | All Wales Medicines Strategy Group (AWMSG) | Drug reviews | Schizophrenia and disorders with psychotic features

NeLM Area:

Evidence > Drug Specific Reviews

Link
5.

RCT: Risperidone, lithium, or divalproex sodium for bipolar I disorder, manic or mixed phase, in children and adolescents

Source: Archives of General Psychiatry,
Date published: 04/01/2012

Category:

4.2.2 Antipsychotic depot injections | Mood disorders (including depression)

NeLM Area:

News

Abstract
6.

Updated IM monograph on Pipotiazine palmitate long acting (depot)

Source: Medusa,
Date published: 23/12/2011

Category:

4.2.2 Antipsychotic depot injections | Drug Administration

NeLM Area:

News

Link- registration required
7.

Treatment patterns and health care resource utilization in a 1-year observational cohort study of outpatients with schizophrenia at risk of nonadherence treated with long-acting injectable antipsychotics

Source: Patient Preference and Adherence,
Date published: 15/12/2011

Category:

4.2.2 Antipsychotic depot injections

NeLM Area:

Evidence > Medicines Management > References

Full text link (PDF)
8.

Explicit review of risperidone long-acting injection prescribing practice

Source: Journal of Clinical Pharmacy and Therapeutics,
Date published: 28/10/2011

Category:

4.2.2 Antipsychotic depot injections

NeLM Area:

Evidence > Medicines Management > References

Abstract link
9.

Piportil Depot Injection 50 mg/ml (pipotiazine palmitate)- Revised SPC

Source: eMC (electronic Medicines Compendium),
Date published: 25/10/2011

Category:

4.2.2 Antipsychotic depot injections

NeLM Area:

Other Library Updates > SPC Changes

SPC
10.

The cost associated with administering risperidone long-acting injections in the Australian community

Source: BMC Health Services Research,
Date published: 07/10/2011

Category:

4.2.2 Antipsychotic depot injections

NeLM Area:

Evidence > Medicines Management > References

Full text link (PDF)

Results 1 - 10 of 62

Result page:
Previous
|
1
2
3
4
5
6
7
|
Next